saascode
biotech, life sciences & pharma·run 073 · May 2026

Tinyvault

A small-pharma commercial and medical operations workspace that adds reviewed HCP planning, interaction evidence, safety handoff, promotional review, transfer tracking, and regulatory milestones around an existing CRM.

Genesis score7.27/10
Make Tinyvault real.0/500
500 more votes and Tinyvault is authorized for build.
0%500 to authorize
Backing is the vote. When an idea crosses 500, we pull it into the build pipeline and ship it for real — the votes decide what gets built next, not an editor.
The opportunity
1Verified public reporting API
0Observed vertical marketplace peers
0Automatic MLR approvals
The case

Small pharma teams may run HCP relationships in a general CRM while safety, medical, promotional review, samples, transfers of value, and regulatory milestones live elsewhere. Tinyvault adds a governed workflow rather than replacing a validated enterprise suite. Agents can prepare source-linked drafts and route cases; qualified people own medical, safety, legal, regulatory, and promotional decisions. A CRM activity is not proof of an HCP interaction, and an audit log is not compliance.

Who pays — and why

The commercial operations, medical affairs operations, compliance, pharmacovigilance, or regulatory operations leader at a small pharmaceutical company.

What it unlocks
HCP and organization identity with source, role, license, territory, consent, and correction
Pre-call packets that separate approved content, public evidence, prior interactions, and prohibited inference
Fast safety-information capture and attributable handoff to qualified pharmacovigilance review
Promotional review, samples, value transfer, milestones, and evidence states with named owners
How Genesis scored it
7.27across seven criteria
tension 6temporal 8blindspot 6buyer 8leverage 8convergence 5why-not 8
8
Temporal window

Current premium agent launches make the gap visible.

8
Buyer persona

Small-pharma operations owners are precise.

5
Convergence

Two cross-references and one inbound link provide moderate support.

Why it scored well

A precise small-pharma buyer, an enterprise-tier gap, a verified public reporting source, and no observed general-CRM vertical app support the direction.

What's holding it back

The product spans several regulated systems, CRM interfaces and partner rights are unverified, enterprise incumbents have deep validation, and services may dominate implementation.

Signals detected4 sources crossed
Signalecosystem research carried in Genesis

Signalmarket research carried in Genesis

Signalofficial documentation carried in Genesis

SignalGenesis market scan

Direction brieftinyvault.md
tinyvault.md
Want this pointed at your vertical?Point Genesis at your own market and constraints — it invents adjacent, fork-ready ideas, private to you before they hit the public feed.

Discussion

?

No comments yet — be the first to weigh in.